» Articles » PMID: 32753468

PD-1 Does Not Mark Tumor-infiltrating CD8+ T Cell Dysfunction in Human Gastric Cancer

Overview
Date 2020 Aug 6
PMID 32753468
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Overexpression of programmed cell death protein 1 (PD-1) is linked to CD8+ T cell dysfunction and contributes to tumor immune escape. However, the prevalence and functional regulations of PD-1 expression on CD8+ T cells in human gastric cancer (GC) remain largely unknown.

Methods: Flow cytometry was performed to analyze the level, phenotype, functional and clinical relevance of PD-1+CD8+ T cells in GC patients. Peripheral blood CD8+ T cells were purified and subsequently exposed to culture supernatants from digested primary GC tumor tissues (TSN) in vitro for PD-1 expression and functional assays. Tumor responses to adoptively transferred TSN-stimulated CD8+ T cells or to the TSN-stimulated CD8+ T cell transfer combined with an anti-PD-1 antibody injection were measured in an in vivo xenograft mouse model.

Results: GC patients' tumors showed a significantly increased PD-1+CD8+ T cell infiltration. However, these GC-infiltrating PD-1+CD8+ T cells showed equivalent function to their PD-1-CD8+ counterparts and they did not predict tumor progression. High level of transforming growth factor-β1 (TGF-β1) in tumors was positively correlated with PD-1+CD8+ T cell infiltration, and in vitro GC-derived TGF-β1 induced PD-1 expression on CD8+ T cells via Smad3 signaling, whereas Smad2 signaling was involved in GC-derived TGF-β1-mediated CD8+ T cell dysfunction. Furthermore, GC-derived TGF-β1-mediated CD8+ T cell dysfunction contributed to tumor growth in vivo that could not be attenuated by PD-1 blockade.

Conclusions: Our data highlight that GC-derived TGF-β1 promotes PD-1 independent CD8+ T cell dysfunction. Therefore, restoring CD8+ T cell function by a combinational PD-1 and TGF-β1 blockade might benefit future GC immunotherapy.

Citing Articles

Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer.

He X, Guan X, Li Y Front Immunol. 2025; 16:1532605.

PMID: 40028336 PMC: 11868122. DOI: 10.3389/fimmu.2025.1532605.


Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy.

Yen Y, Zhang Z, Chen A, Qiu Y, Liu Q, Wang Q J Nanobiotechnology. 2025; 23(1):124.

PMID: 39972327 PMC: 11841268. DOI: 10.1186/s12951-025-03129-z.


Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis.

Wan Z, Cui M, Yang J, Liao D, Chen J, Li F Front Oncol. 2025; 14:1531219.

PMID: 39876901 PMC: 11772205. DOI: 10.3389/fonc.2024.1531219.


THEMIS promotes T cell development and maintenance by rising the signaling threshold of the inhibitory receptor BTLA.

Melique S, Vadel A, Rouquie N, Yang C, Bories C, Cotineau C Proc Natl Acad Sci U S A. 2024; 121(20):e2318773121.

PMID: 38713628 PMC: 11098085. DOI: 10.1073/pnas.2318773121.


Early Increase in Circulating PD-1CD8 T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy.

Shin K, Kim J, Park S, Kim H, Lee M, Kim O Cancers (Basel). 2023; 15(15).

PMID: 37568771 PMC: 10417033. DOI: 10.3390/cancers15153955.


References
1.
Lee H, Chae S, Lee Y, Kim M, Lee H, Lee B . Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008; 99(10):1704-11. PMC: 2584941. DOI: 10.1038/sj.bjc.6604738. View

2.
Thomas D, Massague J . TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005; 8(5):369-80. DOI: 10.1016/j.ccr.2005.10.012. View

3.
Zhao Q, Huang Z, He M, Gao Z, Kuang D . BTLA identifies dysfunctional PD-1-expressing CD4 T cells in human hepatocellular carcinoma. Oncoimmunology. 2017; 5(12):e1254855. PMC: 5214739. DOI: 10.1080/2162402X.2016.1254855. View

4.
Kim S, Cristescu R, Bass A, Kim K, Odegaard J, Kim K . Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018; 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z. View

5.
Saito H, Shimizu S, Kono Y, Murakami Y, Shishido Y, Miyatani K . PD-1 Expression on Circulating CD8 T-Cells as a Prognostic Marker for Patients With Gastric Cancer. Anticancer Res. 2018; 39(1):443-448. DOI: 10.21873/anticanres.13132. View